New Delhi: The Drugs Controller General of India (DCGI) on Sunday (July 4, 2021) approved a licence to Panacea Biotec for creating the Russian COVID-19 vaccine, Sputnik V, in India. The evolution comes after the initial batch of the COVID-19 vaccine cleared all quality-control trials at the Gamaleya Center, Russia. Panacea Biotec, in a release on Sunday, declared that it has received a licence from the DCGI for developing the Sputnik V antibody in its Himachal Pradesh facility.
“Panacea Biotec… (is in) receipt of manufacturing licence from Drugs Controller General (India) for Sputnik V injection against Covid-19 according to its partnership with Russian Direct Investment Fund. The licence is a necessary condition for using Sputnik V created by Panacea Biotec in India,” the pharma company said in an article.
The Managing Director of the organization, Rajesh Jain stated, “Panacea Biotec is thrilled to declare the procurement of the manufacturing licence to produce Sputnik V vaccine in India. On this event, we are obliged to the leadership of Prime Minister Narendra Modi and the government of India for timely hand-holding and facilitating clearances to licence ‘Make in India’ vaccines.”
The pharma company partnered with Russian Direct Investment Fund (RDIF) to produce the COVID-19 vaccine in the country. The Russian antibody, Sputnik V, has been part of India’s challenge against COVID-19 since 14 May.
Sputnik V has been enlisted in 54 nations globally with a total population of over 1.4 billion individuals. The efficacy of Sputnik V is 91.6 percent as assured by the data published in the Lancet, one of the world’s oldest and most respected medical journals.